Morristown-based Pernix Therapeutics Holdings Inc., a specialty pharmaceutical company, announced Monday that it has closed on its transaction to acquire the U.S. rights to a migraine treatment medication.
The medication, Treximet, is a combination of sumatriptan and naproxen sodium that is for the acute treatment of migraine attacks with or without aura in adults. The medication has been delayed due to a short-term supply constraint.
The company is working with GlaxoSmithKline to fix the delay. Pernix and its lenders are also performing additional due diligence to help increase the supply.
“We are working with our lenders to complete our review and remain optimistic about our ability to close the acquisition of Treximet. We hope to complete our due diligence and the financing necessary in the near future,” Doug Drysdale, chairman, president and CEO of Pernix, said.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy